![Rheum Advisor on Air artwork](https://is1-ssl.mzstatic.com/image/thumb/Podcasts123/v4/a8/97/c5/a897c540-69c5-e1e9-133e-d123359aa951/mza_6495222817350516042.png/100x100bb.jpg)
A Closer Look at Pegloticase Treatment in Gout
Rheum Advisor on Air
English - December 10, 2020 18:34 - 10 minutes - 14.2 MBMedicine Health & Fitness health healthcare medicine rheumatology Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Harnessing the Microbiome to Understand Rheumatic Diseases
Next Episode: Time for an Update: ACR RA Management Guidelines
Approved by the US Food and Drug Administration for the treatment of refractory gout, pegloticase, in combination with immunomodulatory agents, is an area of gout treatment that has shown much promise.
Our featured guest on this episode is Brian LaMoreaux, MD, MS, an investigator on many gout studies, who provides an overview of the notable research in pegloticase treatment in gout, as presented at the American College of Rheumatology (ACR) 2020 annual meeting.